HRD status is essential in determining your treatment options.

MyChoice® CDx is the most comprehensive tumor test that determines HRD status in women with ovarian cancer.
What is HRD Status?
There is a pathway called homologous recombination (HR) that fixes DNA damage. But, in some people this ability can be broken, resulting in homologous recombination deficiency (HRD).
Approximately 50% of all ovarian cancer tumors have homologous recombination deficiency. MyChoice® CDx examines ovarian tumors to indicate your HRD status to determine if PARP inhibitor treatment if right for you.

What are PARP inhibitors?
PARP inhibitors are a type of oral medicine that blocks a DNA repair pathway in cancer cells. In people who are HRD positive (HRD+), PARP inhibitors are more likely to work because blocking this DNA repair pathway causes the cancer cell to die. Fortunately, around half of ovarian cancers are HRD positive (HRD+).
To find out if you can benefit from PARP inhibitor therapy, you need to know your HRD status.

How does MyChoice CDx help?
MyChoice CDx is the only FDA-approved companion diagnostic test that determines HRD status in ovarian tumors using two individual methods:

1. *BRCA1* and *BRCA2* status
2. Your genomic instability score - a metric created by Myriad Genetics to determine your tumor’s HRD vulnerability.
What do your results mean?

MyChoice® CDx provides clear answers to HRD status by giving you either a HRD– or HRD+ result

- **HRD–** result means you are less likely to benefit from PARP inhibitor treatment. Your doctor will explain your options to you, which may still include going on a PARP inhibitor.

- **HRD+** result means you are more likely to benefit from PARP inhibitor treatment, and your doctor will discuss which one is best for you.

MyChoice CDx analyzes your tumor only (somatic) and does not determine whether your ovarian cancer is a result of an inherited (hereditary or germline) gene mutation. Myriad offers additional genetic testing to determine if there is also an inherited risk. Ask your provider for more information.

Myriad is committed to illuminating your pathway to the right treatment at the right time.

**Accurate** MyChoice CDx is an FDA-approved tumor test for ovarian cancer. It has been validated in multiple clinical studies and is the only tumor test for HRD status recommended by national guidelines.

**Accessible** Myriad is committed to providing MyChoice CDx results as quickly as possible. Our results are easy to read and provide you and your provider with the necessary information to make important medical decisions.

**Affordable** MyChoice CDx has broad insurance coverage. Myriad will work with your insurance provider to help you receive appropriate coverage. The Myriad Promise™ is our commitment to provide patients with accurate and affordable results. For more information, visit MyriadPromise.com.

Understanding your MyChoice CDx report

The MyChoice CDx report provides clear answers on the HRD status of your tumor to help guide you and your provider through important treatment decisions.

**MyChoice® CDx patient report**

**HRD Status:**
If the MyChoice® CDx test is positive, you may be more likely to benefit from PARP inhibitor therapy.

**Tumor Mutation:**
If a BRCA mutation is found in the tumor, the exact description of the finding, along with its interpretation, will be included in the report to facilitate any downstream hereditary cancer testing.
Approximately 24% of all ovarian cancer results from an inherited mutation.

Hereditary cancer occurs when an altered gene (gene with a mutation) is passed down in the family from parent to child. People with hereditary cancer are more likely to have relatives with the same type of related cancer. They may develop more than one cancer and their cancer often occurs at an earlier than average age.

Familial cancer is likely caused by a combination of genetic and environmental factors. People with familial cancer may have one or more relatives with the same type of cancer; however, there does not appear to be a specific pattern of inheritance (i.e., the cancer risk is not clearly passed from parent to child.)

Sporadic cancer occurs by chance. People with sporadic cancer typically do not have relatives with the same type of cancer.

Why should I do both?

Hereditary genetic testing does not tell you if you have cancer: it informs you and your family if you are at an increased risk of developing other cancers in the future. If you have ovarian cancer, it can also help determine if you are eligible for PARP inhibitor therapy. Even if you do not have an inherited BRCA1/2 mutation, it is still possible that you have a BRCA mutation that is only found within your tumor. Testing for BRCA mutations in your tumor, as well as other features of genomic instability, can determine if you’re eligible for PARP inhibitor therapy.

Per national guidelines, all ovarian cancer patients are eligible for hereditary genetic testing. Ask your provider about your genetic testing options today.
Because patients and their families use test results to make life saving medical decisions, Myriad Genetics promises to provide affordable access to testing, a lifetime commitment to accurate results, and comprehensive support for all appropriate patients and their families.

For more information:
www.myriad-oncology.com/mychoice-cdx
mychoicecdx@myriad.com
877-283-6709